Neurizon Therapeutics Limited has released a press release.
Appendix 4E & Full Year Statutory Accounts 2017
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- PharmAust Shareholders Update
- Epichem reports record $3m revenues & expands laboratory
- Canadian-based specialists to reformulate monepantel
- New European patent granted for non-cancer applications
- PharmAust secures core patent in Japan
Later from Neurizon Therapeutics
- PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
- PharmAust secures core Europe patent
- Reformulation project achieves first milestones and on-track
- New patent secured in US for non-cancer applications
- Monepantel reformulation project continues to progress
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics